FY2027 EPS Estimates for Exelixis Increased by Analyst

Key Points

• Zacks Research raised Exelixis’ FY2027 EPS estimate to $3.59 from $3.57, while maintaining a “Hold” rating. The estimate remains above the current full-year consensus of $3.19.
• Exelixis beat quarterly EPS expectations, reporting $0.91 versus the $0.85 consensus, although revenue of $628.69 million fell short of the $636.40 million estimate. Revenue still increased 10.6% year over year.
• The stock opened at $59.01, near its 52-week high of $59.72, with analysts holding an average “Hold” rating and a $50.07 price target. Institutional investors own 85.27% of the company, led by recent purchases from BlackRock and California State Teachers’ Retirement System.

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Investment analysts at Zacks Research upped their FY2027 earnings per share estimates for shares of Exelixis in a report released on Thursday, September 3rd. Zacks Research analyst Team now forecasts that the biotechnology company will post earnings of $3.59 per share for the year, up from their previous estimate of $3.57. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Exelixis' current full-year earnings is $3.19 per share. Zacks Research also issued estimates for Exelixis' Q1 2028 earnings at $0.97 EPS.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.06. The firm had revenue of $628.69 million during the quarter, compared to the consensus estimate of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%.The firm's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.75 EPS.

Other equities analysts have also issued research reports about the stock. Royal Bank Of Canada boosted their target price on shares of Exelixis from $43.00 to $46.00 and gave the stock a "sector perform" rating in a research report on Tuesday, July 7th. UBS Group set a $55.00 price target on shares of Exelixis in a report on Monday, August 3rd. Citigroup restated a "market outperform" rating on shares of Exelixis in a research report on Wednesday, July 22nd. Morgan Stanley boosted their price objective on shares of Exelixis from $50.00 to $53.00 and gave the stock an "equal weight" rating in a report on Thursday, July 23rd. Finally, Citizens Jmp upped their price objective on shares of Exelixis from $50.00 to $55.00 and gave the company a "market outperform" rating in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $50.07.

Exelixis Stock Performance

EXEL opened at $59.01 on Monday. Exelixis has a 1-year low of $33.76 and a 1-year high of $59.72. The stock has a market capitalization of $14.62 billion, a price-to-earnings ratio of 18.56, a P/E/G ratio of 1.76 and a beta of 0.42. The business has a 50 day moving average of $55.07 and a 200-day moving average of $49.54.

Hedge Funds Weigh In On Exelixis

A number of hedge funds have recently made changes to their positions in EXEL. BlackRock Inc. bought a new stake in Exelixis in the second quarter valued at about $1,581,991,000. California State Teachers Retirement System raised its position in Exelixis by 4,875.6% in the second quarter. California State Teachers Retirement System now owns 14,785,373 shares of the biotechnology company's stock worth $804,472,000 after purchasing an additional 14,488,217 shares in the last quarter. AQR Capital Management LLC lifted its stake in Exelixis by 48.8% during the fourth quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company's stock worth $598,647,000 after purchasing an additional 4,477,029 shares during the period. Invesco Ltd. lifted its stake in Exelixis by 1.6% during the fourth quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company's stock worth $265,379,000 after purchasing an additional 94,218 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Exelixis by 0.9% during the first quarter. Dimensional Fund Advisors LP now owns 4,299,597 shares of the biotechnology company's stock valued at $184,391,000 after purchasing an additional 39,920 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Insider Buying and Selling

In related news, Director Mary Beckerle sold 9,812 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total value of $526,511.92. Following the completion of the transaction, the director directly owned 16,079 shares of the company's stock, valued at $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is currently owned by company insiders.

Exelixis News Summary

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research upgraded Exelixis from “Strong Sell” to “Hold,” improving the tone around the stock. Exelixis is a Top-Ranked Value Stock
• Positive Sentiment: Zacks Research modestly raised its EPS forecasts for Exelixis’ fourth quarter of 2027, second quarter of 2028 and full-year 2028. The FY2028 estimate increased to $4.21 from $4.18, suggesting slightly better long-term earnings expectations.
• Positive Sentiment: Exelixis has broken out to new highs following its earnings report, reflecting continued investor demand and favorable chart momentum. Exelixis Reaches New 52-Week High Following Analyst Upgrade
• Positive Sentiment: The company is being highlighted as a highly ranked value stock, which may attract investors seeking relatively attractive valuation and earnings potential.
• Neutral Sentiment: Investors are watching a potential FDA action tied to the cancer-treatment business. A favorable decision could provide another catalyst, while the timing and outcome remain uncertain. Cancer Stock Breaks Out to Highs
• Negative Sentiment: Despite beating quarterly EPS expectations, Exelixis’ latest revenue came in below consensus estimates. The earnings “snag” means investors may need evidence that growth can accelerate before the breakout is sustained. IBD Stock of the Day Exelixis Hits Earnings Snag and Then Breaks Out

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source